Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule Mediated MEK Degradation 

Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed new synergistic drug combinations between PAC-1 and certain FDA-approved kinase inhibitors. These enhance MEK1/2 kinases degradation, delaying or eliminating the onset of resistance cancer cells.